🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the pathogen, according to scientists.

A Global Challenge

Cases of gonorrhoea are escalating around the world, with estimates suggesting over 82 million instances each year. Especially elevated rates are seen in Africa and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a all-time high, while infection numbers across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an important and timely step in the reality of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options at this time.”

Health officials are increasingly worried about the increase in drug-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.

Two New Therapies Gain Authorization

Zoliflodacin, alternatively called a brand name, was authorized by the American regulatory agency in December for use against gonorrhoea. This infection can lead to major issues, including the inability to conceive. Researchers hope that focused deployment of this new drug will help hinder the development of resistance.

Another new antibiotic, originating from the drugmaker GSK, also received approval in concurrent days. This treatment, which is additionally indicated for urinary tract infections, was shown in trials to be effective against antibiotic-resistant forms of the gonorrhoea bacteria.

An Innovative Approach to Creation

Zoliflodacin stemmed from a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company Innoviva to see it through.

“This milestone marks a major breakthrough in the therapy of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Data and Worldwide Availability

As per data detailed in a prominent scientific publication, the new drug eradicated the vast majority of cases of the STI. This places it at an similar efficacy with the current standard treatment, which uses an injection and a pill. The trial enrolled hundreds of patients from various regions including the United States, Thailand, South Africa, and European nations.

Under the terms of its development partnership, the non-profit has the rights to make available and distribute the drug in many regions with limited resources.

Medical professionals on the front lines have voiced positive views. The availability of a easy-to-administer therapy such as this is described as a "critical tool" for gonorrhoea control. This is viewed as essential to lessen the impact of the illness for individuals and to stop the proliferation of extremely resistant gonorrhoea globally.